[JAMA] Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients

JeniferKarina Post time 5 day(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-10-30 02:11
Reward10points

journalㄩJAMA Oncology

AuthorsㄩXiaoyu Liu; Xiaoyi Xu; Z John Lu; Ya-Chen Tina Shih

Published dateㄩ2026-10-1

DOIㄩ10.1001/jamaoncol.2026.3128

PDF linkㄩhttps://jamanetwork.com/journals ... 792007353.32084.pdf

Article linkㄩhttps://doi.org/10.1001/jamaoncol.2026.3128

Article SourceㄩAmerican Medical Association (AMA)﹝


Remarkㄩ

Best Answer

Please approve

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
Fern21 Post time 5 day(s) ago | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Senior Member
  • post

  • reply

  • points

    590

Return to the list